Last mentioned: Mar 24, 2026
Current Data Release
National reports show abortion numbers holding steady despite 14+ state bans.
Medication Dominance
FDA data confirms medication abortion surpasses surgical procedures as the primary method.
Supreme Court Ruling
SCOTUS maintains access to mifepristone by dismissing a challenge to FDA's rules on procedural grounds.
SCOTUS Mifepristone Hearing
Supreme Court hears arguments regarding the FDA's regulation of medication abortion pills.
National Data Release
Reports confirm U.S. abortion numbers held steady despite 14 state-level bans.
Shield Law Expansion
States like MA and NY implement laws protecting providers from out-of-state legal actions.
Shield Law Expansion
States like MA and NY pass laws protecting telehealth providers mailing pills to ban states.
Pharmacy Certification
FDA updates REMS to allow retail pharmacies to dispense mifepristone upon certification.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, returning abortion regulation to the states.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, allowing state-level bans.
Mail-Order Authorization
FDA permanently removes the requirement for in-person dispensing, allowing for telehealth and mail delivery.
Protocol Expansion
FDA extends usage window to 10 weeks and reduces required office visits from three to one.
Initial FDA Approval
FDA approves mifepristone for medical termination of pregnancy through seven weeks.
Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
New data reveals that the total number of abortions in the United States has remained stable despite a wave of state-level bans and restrictions. This trend is largely driven by the rapid expansion of telehealth services and medication abortion, highlighting a significant shift in how reproductive healthcare is delivered and regulated.
Despite the implementation of near-total bans in 14 states, the national volume of abortions in the U.S. has remained steady or increased. This resilience is driven by a surge in medication abortion, the expansion of telehealth, and the emergence of state 'shield laws' that protect providers across jurisdictional lines.